Robert Graham, MD
Internal Medicine · Nashville, TNNPI 1497789556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 30.2% of the total. Reporting peaked in 2019 at $604 and has fallen 97.4% since, to $16 in 2025.
Across 61 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$298
- AstraZeneca$174
- Amarin Pharma, Inc.$105
- Novartis$81
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$69
- Astellas Pharma US Inc$43
- plus $214 from 10 others
What the payments were for
- Food & beverage$97799%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $298 |
| AstraZeneca | 10 | $174 |
| Amarin Pharma, Inc. | 7 | $105 |
| Novartis | 5 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Astellas Pharma US Inc | 2 | $43 |
| Boehringer Ingelheim | 2 | $37 |
| Amgen | 2 | $32 |
| Merck | 2 | $25 |
| GSK | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $17 |
| Abiomed | 1 | $16 |
| Pfizer | 1 | $16 |
| AbbVie | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$984 in reported general payments places this provider in the 65th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $126,939 |
| FarxigaDapagliflozin Propanediol | 65 | $74,763 |
| JanuviaSitagliptin Phosphate | 50 | $59,202 |
| EliquisApixaban | 39 | $46,272 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $41,591 |
| JardianceEmpagliflozin | 23 | $33,815 |
| InvokanaCanagliflozin | 21 | $22,040 |
| ProliaDenosumab | 12 | $20,091 |
| XareltoRivaroxaban | 23 | $19,804 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $15,317 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $15,301 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $10,718 |
| Atorvastatin Calcium | 672 | $6,673 |
| VascepaIcosapent Ethyl | 14 | $4,875 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $298 | $142,24083 claims |
| AstraZenecaFarxiga | $174 | $74,76365 claims |
| MerckJanuvia | $25 | $59,20250 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $25 | $56,90964 claims |
| PfizerEliquis | $16 | $46,27239 claims |
| Johnson & JohnsonInvokana, Xarelto | $17 | $41,84444 claims |
| Boehringer IngelheimJardiance | $37 | $33,81523 claims |
| AmgenProlia | $32 | $20,09112 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11 | $10,71813 claims |
| AbbVieSynthroid | $12 | $2,99442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Nashville
- John AndersonNashville$1.5M
- Temidayo AbeNashville$113K
- Wayne RileyNashville$86K
- Leah CordovezNashville$64K
- Asad Al AboudNashville$44K
- Mark KouryNashville$41K
- David HeusinkveldNashville$24K
- Charlotte LohreyNashville$19K
- Malek Al-OmaryNashville$18K
- James GekasNashville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.